METHOD FOR PREDICTING STATUS OF EPIDERMAL GROWTH FACTOR HER2/NEU IN METASTATIC LYMPH NODES IN BREAST CANCER PATIENTS Russian patent published in 2021 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to oncology, and concerns a method for predicting the likelihood of a positive status of the epidermal growth factor receptor Her2/neu in metastatic lymph nodes in patients with breast cancer, characterized by the fact that a radionuclide study of metastatic lymph nodes is performed prior to systemic therapy, for which the patient is injected with the radiopharmaceutical "^99mTc - DARPin9_29" at a dose of 1200 mcg, 2 hours after administration, single-photon emission computed tomography (SPECT) of the chest organs is performed, while the accumulation of the labeled protein in the affected axillary lymph node and the symmetrical area of ​​the opposite axillary region is assessed, the node / background ratio is determined and evaluated in points, while the ratio node/background is less than or equal to 5.0, the value is estimated at 1 point, and when the node/background ratio is more than 5.0, the value is estimated at 2 points, then the value of the regression equation Y is calculated using the formula. Next, the probability of a positive status of the epidermal growth factor receptor Her2/neu in the metastatic lymph node P is determined using the formula, where the probability P is expressed as a percentage. If P is more than or equal to 50%, a high probability is predicted, and if P is less than 50%, a low probability of a Her2-positive tissue status of a metastatic tumor node is predicted. Model confidence level: p = 0.000; χ2 = 55.45.

EFFECT: 100% sensitivity and specificity of the model is achieved.

1 cl, 2 ex